69.19
0.23 (0.33%)
| Penutupan Terdahulu | 68.96 |
| Buka | 67.90 |
| Jumlah Dagangan | 11,172,857 |
| Purata Dagangan (3B) | 1,971,356 |
| Modal Pasaran | 12,579,216,384 |
| Harga / Jualan (P/S) | 31.91 |
| Harga / Buku (P/B) | 45.07 |
| Julat 52 Minggu | |
| Tarikh Pendapatan | 8 May 2025 |
| Margin Keuntungan | -251.24% |
| Margin Operasi (TTM) | -234.79% |
| EPS Cair (TTM) | -5.57 |
| Pertumbuhan Hasil Suku Tahunan (YOY) | 24.80% |
| Jumlah Hutang/Ekuiti (D/E MRQ) | 459.02% |
| Nisbah Semasa (MRQ) | 5.45 |
| Aliran Tunai Operasi (OCF TTM) | -683.88 M |
| Aliran Tunai Bebas Leveraj (LFCF TTM) | -418.30 M |
| Pulangan Atas Aset (ROA TTM) | -29.30% |
| Pulangan Atas Ekuiti (ROE TTM) | -890.75% |
Arah Aliran Pasaran
| Jangka Pendek | Jangka Sederhana | ||
| Industri | Biotechnology (US) | Bercampur | Bercampur |
| Biotechnology (Global) | Bercampur | Bercampur | |
| Stok | Insmed Incorporated | Menurun | Menaik |
AISkor Stockmoo
| Konsensus Penganalisis | 1.0 |
| Aktiviti Orang Dalam | -1.5 |
| Volatiliti Harga | 2.0 |
| Purata Bergerak Teknikal | 0.0 |
| Osilator Teknikal | -2.0 |
| Purata | -0.10 |
|
Insmed Inc is a global biopharmaceutical company transforming the lives of patients with serious and rare diseases. The company's first commercial product is ARIKAYCE (amikacin liposome inhalation suspension), approved in the US for the treatment of Mycobacterium Avium Complex (MAC) lung disease as part of a combination antibacterial drug regimen for adult patients with limited or no alternative treatment options. The company's earlier-stage clinical pipeline includes Brensocatib, a novel oral reversible inhibitor of dipeptidyl peptidase 1 with therapeutic potential in non-cystic fibrosis bronchiectasis and other inflammatory diseases; and INS1009, an inhaled formulation of a treprostinil prodrug that may offer a differentiated product profile for pulmonary arterial hypertension. |
|
| Sektor | Healthcare |
| Industri | Biotechnology |
| Gaya Pelaburan | Mid Growth |
| % Dimiliki oleh Orang Dalam | 0.82% |
| % Dimiliki oleh Institusi | 111.85% |
Pemilikan
| Nama | Tarikh | Syer Dipegang |
|---|---|---|
| Darwin Global Management, Ltd. | 31 Dec 2024 | 12,960,538 |
| Julat 52 Minggu | ||
| Julat Harga Sasaran | ||
| Tinggi | 110.00 (UBS, 58.99%) | Beli |
| Median | 98.00 (41.65%) | |
| Rendah | 90.00 (HC Wainwright & Co., 30.09%) | Beli |
| 90.00 (Morgan Stanley, 30.09%) | Beli | |
| Purata | 99.00 (43.10%) | |
| Jumlah | 10 Beli | |
| Harga Purata @ Panggilan | 78.82 | |
| Syarikat | Tarikh | Harga Sasaran | Panggilan | Harga @ Panggilan |
|---|---|---|---|---|
| HC Wainwright & Co. | 22 Apr 2025 | 90.00 (30.09%) | Beli | 71.24 |
| 24 Feb 2025 | 90.00 (30.09%) | Beli | 80.03 | |
| B of A Securities | 20 Mar 2025 | 96.00 (38.76%) | Beli | 78.77 |
| RBC Capital | 19 Mar 2025 | 100.00 (44.54%) | Beli | 78.94 |
| 25 Feb 2025 | 100.00 (44.54%) | Beli | 77.50 | |
| UBS | 06 Mar 2025 | 110.00 (58.99%) | Beli | 75.02 |
| Guggenheim | 25 Feb 2025 | 101.00 (45.99%) | Beli | 77.50 |
| 07 Feb 2025 | 101.00 (45.99%) | Beli | 79.95 | |
| Stifel | 21 Feb 2025 | 96.00 (38.76%) | Beli | 81.06 |
| 11 Feb 2025 | 97.00 (40.20%) | Beli | 79.89 | |
| Truist Securities | 21 Feb 2025 | 108.00 (56.10%) | Beli | 81.06 |
| Wells Fargo | 19 Feb 2025 | 107.00 (54.66%) | Beli | 83.83 |
| JP Morgan | 07 Feb 2025 | 92.00 (32.98%) | Beli | 79.95 |
| Morgan Stanley | 06 Feb 2025 | 90.00 (30.09%) | Beli | 80.78 |
| Papar semua | ||||
| Nama | Purata Belian ($) | Purata Jualan ($) | Jumlah Net | Jumlah Nilai Bersih ($) |
|---|---|---|---|---|
| LEWIS WILLIAM | - | 71.07 | -6,830 | -485,408 |
| Jumlah Keseluruhan Kuantiti Bersih | -6,830 | |||
| Jumlah Keseluruhan Nilai Bersih ($) | -485,408 | |||
| Purata Pembelian Keseluruhan ($) | - | |||
| Purata Jualan Keseluruhan ($) | 71.07 | |||
| Nama | Pemegang | Tarikh | Jenis | Kuantiti | Harga | Nilai ($) |
|---|---|---|---|---|---|---|
| LEWIS WILLIAM | Pegawai | 15 Apr 2025 | Jual automatik (-) | 6,830 | 71.07 | 485,408 |
| LEWIS WILLIAM | Pegawai | 15 Apr 2025 | Pelaksanaan pilihan | 6,830 | - | - |
Tahap sokongan, rintangan dan garis aliran yang dibentangkan telah dihasilkan oleh model kecerdasan buatan (AI) dan harus ditafsirkan dengan berhati-hati.
Portfolio
| Keuntungan Nyata | - |
| Keuntungan Tidak Nyata | - |
| Dividen Diterima 2025 | - |
| Jumlah Untung | - |
| Pulangan Purata | - |
| Kuantiti (Beli) | - |
| Purata Harga (Beli) | - |
| Kuantiti (Jual) | - |
| Purata Harga (Jual) | - |